Rice Hall James & Associates LLC Increases Position in Repligen Corporation (NASDAQ:RGEN)

Rice Hall James & Associates LLC raised its stake in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 26.4% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 19,449 shares of the biotechnology company's stock after purchasing an additional 4,058 shares during the period. Rice Hall James & Associates LLC's holdings in Repligen were worth $2,475,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Louisiana State Employees Retirement System boosted its stake in shares of Repligen by 0.7% in the 1st quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the biotechnology company's stock worth $1,858,000 after buying an additional 100 shares during the last quarter. Stephens Investment Management Group LLC increased its position in shares of Repligen by 0.5% during the first quarter. Stephens Investment Management Group LLC now owns 539,542 shares of the biotechnology company's stock valued at $68,651,000 after acquiring an additional 2,741 shares during the last quarter. New York State Common Retirement Fund increased its position in shares of Repligen by 7.6% during the first quarter. New York State Common Retirement Fund now owns 625,388 shares of the biotechnology company's stock valued at $79,574,000 after acquiring an additional 43,946 shares during the last quarter. Diversify Wealth Management LLC increased its position in shares of Repligen by 11.2% during the first quarter. Diversify Wealth Management LLC now owns 3,717 shares of the biotechnology company's stock valued at $518,000 after acquiring an additional 375 shares during the last quarter. Finally, State of Michigan Retirement System increased its position in shares of Repligen by 0.8% during the first quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company's stock valued at $1,585,000 after acquiring an additional 100 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Analyst Ratings Changes

RGEN has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $180.00 price target on shares of Repligen in a research report on Monday, May 5th. Barclays began coverage on Repligen in a research report on Tuesday, June 24th. They set an "overweight" rating and a $150.00 price target for the company. Wall Street Zen cut shares of Repligen from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Royal Bank Of Canada lowered their price target on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a report on Wednesday, April 30th. Finally, Canaccord Genuity Group lowered their price target on shares of Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a report on Wednesday, April 16th. Five investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $170.75.

Repligen Price Performance

Shares of RGEN traded down $7.75 during mid-day trading on Friday, reaching $116.29. 618,710 shares of the stock traded hands, compared to its average volume of 741,544. The firm has a fifty day moving average price of $124.79 and a 200 day moving average price of $138.70. The company has a market cap of $6.53 billion, a price-to-earnings ratio of -258.51, a price-to-earnings-growth ratio of 3.43 and a beta of 1.11. The company has a current ratio of 6.79, a quick ratio of 5.79 and a debt-to-equity ratio of 0.27. Repligen Corporation has a 1 year low of $102.96 and a 1 year high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.35 by $0.04. Repligen had a negative net margin of 3.93% and a positive return on equity of 4.53%. The company had revenue of $169.17 million during the quarter, compared to analyst estimates of $163.65 million. During the same period in the previous year, the business earned $0.28 earnings per share. The firm's quarterly revenue was up 10.4% compared to the same quarter last year. As a group, equities research analysts predict that Repligen Corporation will post 1.72 earnings per share for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.